A cewar masana kimiyya, magungunan da ake amfani da shi don maganin ciwon sukari na 2 zai iya haifar da raguwar haɗarin kamuwa da cutar ta Parkinson.
Masana kimiyyar kasar Norway sun gano cewa a cikin marassa lafiyar da suka yi amfani da miyagun ƙwayoyi Glutazone (GTZ), haɗarin kamuwa da cuta mai lalacewa ya ragu kwata idan muka yi la'akari da kashi. GTZ, wanda aka sani a Rasha a ƙarƙashin sunan Thiazolidinedione, ana amfani dashi don nau'in ciwon sukari na biyu. Tare da shi, zaku iya haɓaka hankalin mutum zuwa insulin, wanda ke da alhakin daidaita matakan sukari na jini.
Don nemo alaƙar da ke tsakanin amfani da cutar ta GTZ da cutar ta Parkinson, masana kimiyya sun yi wani bincike game da marasa lafiya da aka basu wannan magani kamar yadda aka umurce su. Masu binciken sun kuma jawo hankulan su kan yadda metformin, wanda ke cikin magungunan da aka wajabta don nau'in ciwon sukari na biyu, yana shafar ci gaban cutar ta Parkinson. A cikin shekaru goma daga Janairu 2005 zuwa Disamba 2014, masu bincike sun gano fiye da mutane dubu 94.3 waɗanda ke amfani da metformin, kuma kusan wasu 8.4 dubu na GTZ.
Dangane da sakamakon aikin kimiyya, an nuna cewa marasa lafiya waɗanda suka yi amfani da sabon magani, kusan na uku suna da ƙananan hanzari don inganta cutar ta Parkinson. Masana kimiyya basu da isasshen bayani don yin cikakken bayani daidai game da abin da ya samo asali daga bincikensu, amma sun yi imanin cewa GTZ yana haifar da mafi kyawun aikin mitochondrial.
"Wataƙila haɗin kwayar mitochondrial DNA da kuma yawan sunan iri ɗaya yana ƙaruwa da magungunan GTZ," marubutan binciken sun faɗi.
A cewar masana kimiyya, binciken na iya zama tushen sababbin dabarun dabarun dangane da yin rigakafi da lura da cutar ta Parkinson.
Marubucin ya ce "Sabuwar bayanin da muka gano ya kara kusancin warware matsalolin da suka shafi cutar ta Parkinson," in ji marubucin.
